Videos

ON-DEMAND WEBINAR: Maximizing Structural Heart Workflows

ON-DEMAND Webinar: Maximizing Structural Heart Workflows: Harnessing the Power of CVIS and AI
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      January 30, 2025

      On July 16, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Maximizing Structural Heart Workflows: Harnessing the Power of CVIS and AI." 

      During the webinar, Omer Schalit–Cohen, chief product officer at Optum’s Healthcare Enterprising Imaging business unit, addressed optimizing workflow and efficiencies in the cardiovascular imaging department.  In the presentation, Cohen examines how you can harness the power of the CVIS and AI technologies to enhance structural heart workflow in the EP lab and ultrasound procedures.

      Schalit–Cohen is the chief product officer at Optum’s Healthcare Enterprising Imaging business unit. With more than 20 years of experience in innovation, he is an expert in the Imaging’s department complex workflows and has been instrumental in driving market leading solutions that have significantly enhanced patient care and department’s efficiency. as well as customer satisfaction.
       

      Company Profile

      The webinar is sponsored by Optum, a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 215,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group.

      For more information, visit optum.com.

      Recent Video

      January 30, 2025

      On July 16, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Maximizing Structural Heart Workflows: Harnessing the Power of CVIS and AI." 

      During the webinar, Omer Schalit–Cohen, chief product officer at Optum’s Healthcare Enterprising Imaging business unit, addressed optimizing workflow and efficiencies in the cardiovascular imaging department.  In the presentation, Cohen examines how you can harness the power of the CVIS and AI technologies to enhance structural heart workflow in the EP lab and ultrasound procedures.

      Schalit–Cohen is the chief product officer at Optum’s Healthcare Enterprising Imaging business unit. With more than 20 years of experience in innovation, he is an expert in the Imaging’s department complex workflows and has been instrumental in driving market leading solutions that have significantly enhanced patient care and department’s efficiency. as well as customer satisfaction.
       

      Company Profile

      The webinar is sponsored by Optum, a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 215,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group.

      For more information, visit optum.com.

      January 07, 2025

      On Jan. 10, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Contrast Management in Modern PCI." 

      Dr. Aditya Sharma, MD, MBA, FACC, FSCAI, an interventional cardiologist from Wellspan Health in Central Pennsylvania was the presenter. The webinar is sponsored by ACIST Medical Systems.

      In the cardiac cath lab, the use of iodinated contrast in both diagnostic and PCI procedures is commonplace. The effects of iodinated contrast on renal function have been known and researched. However, conversations are ongoing around best practices and standards of care regarding contrast management and treatment for those with higher risk factors, like compromised renal function. Participate in this webinar to gain insight on the topic of contrast-induced kidney injury and how one could approach contrast management in modern PCI with use of the ACIST CVi Contrast Delivery System.

      Learning Objectives

      * Understand basic mechanisms of contrast induced kidney injury.
      * Determine incidence of disease along with long term patient and economic implications.
      * Review risk factors determining higher risk populations.
      * Evaluate device strategy in modern era to mitigate risk and promote procedural efficiency and safety.
      * Case review of use of the ACIST CVi Contrast Delivery System in high risk patient. 

      Dr. Aditya Sharma
      Dr Aditya Sharma

      Dr. Sharma is board certified in internal medicine, cardiovascular disease, and interventional cardiology, having completed both residency and fellowship programs at George Washington University - School of Medicine and Hospital. He chose a career in medicine to be able to help others while being able to continuously enrich his skills and apply learned scientific knowledge.

      About ACIST

      Physicians worldwide rely on our diagnostic technologies to give them the power to visualize, assess and inform patient treatment. ACIST informs interventional decisions during peripheral, cardiovascular disease and structural heart procedures. Economic decision-makers appreciate our ability to demonstrate the value of therapeutic intervention.

      January 01, 2025

      Preventing contrast induced nephropathy and managing patients with chronic kidney disease remain major challenges in the cardiac catheterization lab. In recent years, contrast supply shortages have presented a new challenge to care delivery. When considering these challenges, and as quality metrics in our labs face more scrutiny, there are existing technologies and best practices such as a variable rate contrast delivery systems and HD IVUS that can be used to manage workflow and improve patient outcomes.

      The ACC Interventional Council’s recent statement recommending that intracoronary imaging be a routine part of clinical practice further reinforces the need for adoption of intracoronary. Using a case-based approach, the faculty will demonstrate how to use the ACIST CVi contrast delivery system, HDi high definition IVUS and diagnostic and post-PCI physiologic assessment to reduce contrast usage, improve AKI rates and deliver optimized patient outcomes.

      Learning Objectives

      By the end of this webinar, participants will understand that high-quality care starts at the point of education and can transform cardiovascular imaging. Attendees will see how optimized workflows can improve quality and will be able to:

      • To understand the benefits of implementing a variable rate contrast delivery system in the cath lab.

      • To understand the clinical benefits of HD IVUS utilization and how to implement a standardized workflow for effective use.

      • To understand how HD IVUS and physiologic testing can be used to improve patient outcomes and reduce contrast utilization.

      Featured Speakers

      headshot

      Dr. Matheen A. Khuddus, Director of Cardiovascular Research/Director of the Cardiac Catheterization Lab, HCA Florida North Florida Hospital and the Cardiac & Vascular Institute, Gainesville, Fla.

      Dr. Khuddus is an interventional cardiologist who currently serves as the Director of Cardiovascular Research and the Director of the Cardiac Catheterization Lab as well as a National Physician Director for HCA Healthcare. He is a fellow of the ACC and SCAI.  He is board certified in Cardiovascular Medicine, Interventional Cardiology, and Internal Medicine.  He is also an AHSCP Clinical Hypertension Specialist.



      headshot

      Dr. Darshan Doshi, Director of Complex Coronary Artery Disease, Massachusetts General Hospital, Boston, Mass.

      Dr. Doshi is an interventional cardiologist who specializes in complex coronary intervention, specifically chronic total occlusions, surgical turndowns, ultralow and zero contrast stenting procedures, and treatment of recurrent stent blockages. He is the Director of Complex Coronary Artery Disease at MGH. He is board certified in Cardiovascular Medicine and Interventional Cardiology.

      About ACIST

      Physicians worldwide rely on our diagnostic technologies to give them the power to visualize, assess and inform patient treatment. ACIST informs interventional decisions during peripheral, cardiovascular disease and structural heart procedures. Economic decision-makers appreciate our ability to demonstrate the value of therapeutic intervention.

      January 24, 2025

      Behavioral science is being applied in unique ways for enterprise-imaging product design.

      Behavioral science is the study of human behavior. It’s a mix of psychology, sociology, social and cultural anthropology, and economics. Using a data-driven, human-centered approach, behavioral science helps uncover what people have done in the past and tries to predict — and often change — how they’ll behave in the future.

      In this webinar, leading healthcare experts will discuss how observation, interviews, and experimentation can help the industry form a better understanding of current customer needs and pain points within cardiovascular imaging. Having clinicians involved in the product-design process has led to the complete rearchitecting of a next-generation hemodynamics solution.

      Using a real-world scenario, we’ll share a clinician’s experience working with behavioral science and product-development teams, provide an understanding of how they’re using hemodynamics today, and get their thoughts on the future of imaging and hemodynamics.

      By listening to key stakeholders, new features can be brought to market that will have a notable impact on the way health systems operate. By building better products, we can help improve patient outcomes and ultimately transform the healthcare industry — one behavior at a time.

      Learning Objectives

      • How a next-generation hemodynamics system has implemented 19 user-centric concepts and undergone iterative testing with healthcare providers.

      • How physicians, technicians, nurses and administrators are providing their expertise to bring new features to market that will have a notable impact on the way health systems operate.

      • What a next-generation hemodynamics system can do to keep pace with new technology innovations in cardiovascular care and increasing clinical demands.

      Featured Speakers

      James Stinnett

      James Stinnett, Behavioral Scientist, Change Healthcare

      James Stinnett is an experienced researcher with a background in product, UX, and behavioral science. He joined Change Healthcare three years ago and is currently a researcher on the behavioral science team.

      Dr. Barry Bertolet

      Dr. Barry Bertolet, Interventional Cardiologist and Director of Cardiac Catheterization Laboratory, North Mississippi Medical Center

      Dr. Barry Bertolet champions the education of physicians and patients throughout the region and has participated in numerous research trials exploring early detection and treatment of cardiovascular diseases. He is a founding member of the Mississippi Health Care Alliance, an organization which has developed the nation’s first statewide system of care for both heart attack and stroke. He is also board certified by the American Board of Internal Medicine in cardiovascular disease, internal medicine and interventional cardiology.

      About Change Healthcare

      Change Healthcare is a leading independent healthcare technology company, focused on insights, innovation and accelerating the transformation of the healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.

      Cardiovascular Clinical Studies | July 30, 2024

      As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits down with Philip B. Adamson, MD, MSc, FACC, Chief Medical Officer of CVRx, to talk about health equity — starting at the beginning of clinical trials, and including how medical device manufacturers need a clear roadmap from the get-go to achieve success.

      As Chief Medical Officer of CVRx, Dr. Adamson will spearhead efforts to drive awareness and appropriate use of Barostim therapy among clinicians. He will guide comprehensive medical education, outreach and guideline integration initiatives to establish Barostim as the standard of care for patients with heart failure. Dr. Adamson previously was with Abbott Laboratories, where he served as Divisional Vice President and Chief Medical Officer of the Heart Failure division. A renowned expert in heart failure, he has nearly three decades of experience in academia as a professor and as a practicing cardiologist, during which time he authored over 150 manuscripts and book chapters. Dr. Adamson earned his MD with distinction from the University of Oklahoma College of Medicine and MSc in physiology from the University of Oklahoma.

      His clinical interests focus on developing more efficient and effective disease management systems for patients with chronic heart failure, specifically focusing on remote monitoring of physiologic signals from implanted devices. He has also served as the principal investigator on the steering committees of several large randomized clinical trials over the past decade.

      Related content:

      DAIC Thought Leadership Series: Practical Realities of Artificial Intelligence in Echocardiology

      DAIC Thought Leadership Series: Collaboration Challenges in Complex Cardiology Settings

       

      Artificial Intelligence | July 29, 2024

      In DAIC's continuing Thought Leadership Series with Dr. Jeffrey Soble, a practicing cardiologist at Rush University Medical Group’s Cardiology Intensive Care Unit, and CEO of Ascend Cardiovascular, he addresses the practical realities of artificial intelligence in echocardiology, the primary challenges echocardiographers face that AI support, and where he sees cardiovascular technology headed in the next three years. You can watch the first segment, DAIC Thought Leadership Series: Collaboration Challenges in Complex Cardiology Settings, here.

      Related content:

      DAIC Thought Leadership Series: Collaboration Challenges in Complex Cardiology Settings

      Virtual and Augmented Reality | July 26, 2024

      In this segment of our DAIC Thought Leadership Series, which features one-on-one conversations with cardiovascular leaders, we're talking with Dr. Jeffrey Soble. He serves both as a practicing cardiologist at Rush University Medical Group’s Cardiology Intensive Care Unit, and CEO of Ascend Cardiovascular. In this video he addresses some of the challenges related to collaborating in complex cardiology settings, and provides insight into ways telepresence and augmented reality can be used — from a clinical perspective, using a holistic approach to structured reporting.

      HIMSS | July 24, 2024

      Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and Management Systems Society (HIMSS) Global Conference and Exhibition seems particularly poised to deliver the best of the best when it comes to digital transformation in both the delivery of healthcare, but also the delivery of a quality experience for those in this demanding, rapidly evolving industry. This month in our ongoing One on One series with industry leaders, we are talking with Hal Wolf, FHIMSS, president and CEO of HIMSS. He offered insights on the society’s new partnership with Informa Markets, key topics being covered at HIMSS24, AI’s impact on the industry, and his thoughts on healthcare sustainability.

      Find more HIMSS24 conference coverage here

      A New Partnership for Growth

      Last August, Informa Markets and HIMSS announced a landmark partnership to propel the growth and evolution of the HIMSS Global Health Conference and Exhibition, recognized as the most influential healthcare technology event of the year, and in North America. It draws 40,000 health professionals, tech leaders, providers and governmental organizations from across the globe. Informa Markets, the world’s largest exhibition organizer, took on management of the HIMSS Exhibition, while HIMSS continues to oversee developing expert content and programming.

      Exciting New Features at HIMSS24

      At HIMSS2024, with this new collaboration comes new features, including:

      Related content:

      Find more HIMSS24 conference coverage here

      HIMSS Launches Modernized Infrastructure Adoption Model to Support Global Digital Health Transformation

      Top Public Policy Experts at HIMSS24 to Address Global AI Landscape and Digital Transformation in Healthcare

      VIDEO: Using Maturity Models to Measure Digital Health

      VIDEO: Moving Digital Transformation Forward in Healthcare

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      Pharmaceuticals | September 26, 2023

      In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at Harvard’s Seidman Lab, and how she views the value of learning from and mentoring a new generation of researchers. 

      Part 1 in this 3-part series delved into the research and treatments of the heart muscle disorder, hypertropic cardiomyopathy. You can view VIDEO, Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader, here.

      In Part 2 of this series with Dr. Christine Seidman, a discussion on the discovery of gene-based diagnostics at Harvard’s Seidman Lab which allowed for targeted disease treatment of hypertrophic cardiomyopathy. You can watch Part 2: Hypertrophic Cardiomyopathy in Focus, here.

      Related Hypertrophic Cardiomyopathy content:

      Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

      Part 2: Hypertrophic Cardiomyopathy in Focus

      Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

      Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

      First International Guidelines on Heart Muscle Diseases Published

      Pharmaceuticals | September 11, 2023

      In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based diagnostics at Harvard’s Seidman Lab which allowed for targeted disease treatment of hypertrophic cardiomyopathy.  

      Part 1 in this 3-part series delved into the research and treatments of the heart muscle disorder, hypertropic cardiomyopathy. You can view VIDEO, Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader, here.

      The third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman will discuss what’s on the horizon at Harvard’s Seidman Lab, and how she views the value of learning from and mentoring a new generation of researchers. 

      Related Hypertrophic Cardiomyopathy content:

      Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

      VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

      Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

      Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

      First International Guidelines on Heart Muscle Diseases Published

      Pharmaceuticals | August 28, 2023

      A 3-part video series with Christine E. Seidman, MD, FACC, FAHA

      In the first of this 3-part “One on One” series, Dr. Christine Seidman — recognized as one of the world’s most respected physician scientists — delves into the research and treatments of the heart muscle disorder, hypertrophic cardiomyopathy.  

      In part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based diagnostics at Harvard’s Seidman Lab which allowed for targeted disease treatment of hypertrophic cardiomyopathy. Watch Part 2: Hypertrophic Cardiomyopathy in Focus, here.

      Don’t miss the third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman. Learn what’s on the horizon at Harvard’s Seidman Lab, and how she views the value of learning from and mentoring a new generation of researchers. 

      Related Hypertrophic Cardiomyopathy content:

      VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

      Part 2: Hypertrophic Cardiomyopathy in Focus

      Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

      Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

      Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

      First International Guidelines on Heart Muscle Diseases Published

      Information Technology | May 17, 2023

      HIMMS is working to bring empirical knowledge and evidence of value and impact of digital maturity measured by the HIMSS maturity models and the Digital Health Indicator (DHI), which is a blueprint for digital health advancement. The maturity models provide prescriptive frameworks to healthcare organizations to help build their digital health ecosystems. DAIC spoke with Anne Snowdon, RN, PhD, FAAN, professor of strategy entrepreneurship, Odette Business School, University of Windsor, CEO of SCAN Health and Chief Scientific Research Officer, HIMSS Analytics, to find out more about these models, and what the latest scientific research is telling us.

      Dr. Anne Snowdon is a Professor of Strategy and Entrepreneurship at the Odette School of Business, University of Windsor.  Currently, Dr. Snowdon is the Chief Scientific Research Officer for HIMSS, Vice Chair of the Board of the Directors for Alberta Innovates, and member of the Health Futures Council of Arizona State University (ASU).  She is an Adjunct Faculty at the Department of Computer Science at the University of Windsor, the School of Nursing at Dalhousie University and the Centre for Innovative Medical Technology (CIMT), at the University of Southern Denmark.  Dr. Snowdon is leading a national Community of Practice to advance supply chain resilience across Canada, she has published more than 150 research articles, papers and cases, has received over $24 million in research funding, holds patents and has commercialized a highly successful booster seat product for children traveling in vehicles and is a Fulbright Scholar. She holds a PhD in Nursing from the University of Michigan, an MSc from McGill University, and BScN from Western University.  

      Find more HIMSS23 coverage here

      VIDEO: Moving Digital Transformation Forward in Healthcare

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

       

      Related Digital Transformation Content:

      Robocath Launches New Robotic Platform R-One+

      VIDEO: Using Maturity Models to Measure Digital Health

      VIDEO: Moving Digital Transformation Forward in Healthcare

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      New ACC President Defines Priorities for Year Ahead

      Health That Connects + Tech That Cares at HIMSS 2023

      ACC22: Transforming Cardiovascular Care

       

       

      Information Technology | May 11, 2023

      Healthcare is constantly evolving, finding new ways to innovate and advance digital tools and technology. With this comes the need for transformation to keep up with these advancements. DAIC spoke with Anne Snowdon, RN, PhD, FAAN, professor of strategy entrepreneurship, Odette Business School, University of Windsor, CEO of SCAN Health and Chief Scientific Research Officer, HIMSS Analytics, to find out more about the steps needed for this transformation and what we can expect to see in the future of healthcare.

      Dr. Anne Snowdon is a Professor of Strategy and Entrepreneurship at the Odette School of Business, University of Windsor.  Currently, Dr. Snowdon is the Chief Scientific Research Officer for HIMSS, Vice Chair of the Board of the Directors for Alberta Innovates, and member of the Health Futures Council of Arizona State University (ASU).  She is an Adjunct Faculty at the Department of Computer Science at the University of Windsor, the School of Nursing at Dalhousie University and the Centre for Innovative Medical Technology (CIMT), at the University of Southern Denmark.  Dr. Snowdon is leading a national Community of Practice to advance supply chain resilience across Canada, she has published more than 150 research articles, papers and cases, has received over $24 million in research funding, holds patents and has commercialized a highly successful booster seat product for children traveling in vehicles and is a Fulbright Scholar. She holds a PhD in Nursing from the University of Michigan, an MSc from McGill University, and BScN from Western University.  

      Find more HIMSS23 coverage here

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      Related Digital Transformation Content:

      Robocath Launches New Robotic Platform R-One+

      VIDEO: Using Maturity Models to Measure Digital Health

      VIDEO: Moving Digital Transformation Forward in Healthcare

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      New ACC President Defines Priorities for Year Ahead

      Health That Connects + Tech That Cares at HIMSS 2023

      ACC22: Transforming Cardiovascular Care

      Artificial Intelligence | April 26, 2023

      Successfully creating and implementing artificial intelligence (AI) and analytic solutions in general requires a number of key factors, including data quality and a certain level of expertise. DAIC had a conversation with Julius Bogdan, a leading expert in Digital transformation, Data and analytics, and Artificial intelligence and machine learning, to learn more about the key components needed to create and implement AI and digital transformation solutions.

      Julius is Vice President and General Manager, Digital Health Advisory Team for the Healthcare Information and Management Systems Society (HIMSS). In that role, he leads sales, business development, product management, product marketing and advisory services teams across the continent on digital health transformation. He is responsible for the growth of the HIMSS Analytics portfolio adoption, channel strategy, and cultivating relationships across the provider, payer and public sector health landscape. He also serves on the advisory council of various start-ups and early stage firms in finance and healthcare on technology trends, architecture and market analysis.

      Find more HIMSS23 content here 

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      Related Digital Transformation Content:

      Robocath Launches New Robotic Platform R-One+

      VIDEO: Using Maturity Models to Measure Digital Health

      VIDEO: Moving Digital Transformation Forward in Healthcare

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      New ACC President Defines Priorities for Year Ahead

      Health That Connects + Tech That Cares at HIMSS 2023

      ACC22: Transforming Cardiovascular Care

      Artificial Intelligence | April 25, 2023

      With the help of artificial intelligence, cutting-edge technology is being developed that will help improve patient outcomes and build efficiencies in healthcare, which will help transform the future of healthcare delivery. DAIC sat down with Julius Bogdan, a leading expert in Digital transformation, Data and analytics, and Artificial intelligence and machine learning, to find out more about the inroads AI is making.

      Julius is Vice President and General Manager, Digital Health Advisory Team for the Healthcare Information and Management Systems Society (HIMSS). In that role, he leads sales, business development, product management, product marketing and advisory services teams across the continent on digital health transformation. He is responsible for the growth of the HIMSS Analytics portfolio adoption, channel strategy, and cultivating relationships across the provider, payer and public sector health landscape. He also serves on the advisory council of various start-ups and early stage firms in finance and healthcare on technology trends, architecture and market analysis.

      Find more HIMSS23 content here

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      Related Digital Transformation Content:

      Robocath Launches New Robotic Platform R-One+

      VIDEO: Using Maturity Models to Measure Digital Health

      VIDEO: Moving Digital Transformation Forward in Healthcare

      VIDEO: Key Components to Creating and Implementing AI and Digital Transformation Solutions

      VIDEO: The Benefits and Pitfalls of Artificial Intelligence in Healthcare

      VIDEO: A Look at Cybersecurity and How Healthcare is at Risk

      New ACC President Defines Priorities for Year Ahead

      Health That Connects + Tech That Cares at HIMSS 2023

      ACC22: Transforming Cardiovascular Care

      Womens Cardiovascular Health | February 01, 2023

      Managing Acute Coronary Syndromes in Women: Why and When is a Unique Approach Required features an in-depth interview with Malissa J. Wood, MD, FACC. Wood is the co-director of the Corrigan Women’s Heart Health Program at Massachusetts General Hospital Heart Center, and associate professor at Harvard Medical School. Here, she offers detailed guidance to cardiologists for improving the diagnosing and treatment of heart disease in women. Wood serves as the American College of Cardiology, ACC Chair, Board of Governors, and Secretary, Board of Trustees (2022-2023). This video interview is part of DAIC's One on One ... feature series that profiles a leader in cardiology to share insight, updates and initiatives on a range of hot topics impacting the cardiology community. The series also includes a feature profile and podcast.

      Related content:

      VIDEO: Precision Cardiovascular Medicine: The Next Frontier in Patient Care and Innovation

      VIDEO: Unique Features of Coronary Artery Disease in Women

      Treatment for Heart Attacks Improving but Gaps in Access Persist, New Study Shows

      Closing the Gap in Healthcare by Addressing Gender Bias 

      Diagnostic Differences in Women’s Heart Health  

      VIDEO: Differences in Cardiac Complications and Presentation Between Men and Women — Interview with Cindy Grines, M.D.  

      DAIC's Women's Cardiovascular Health Channel  

      VIDEO: How to Build a Successful Women’s Heart Center — Interview with Malissa Wood, M.D.  

      VIDEO: Creating a Cardio-Obstetrics Team — Doreen DeFaria Yeh, M.D. 

      Related Content on New Technology and Ideas to Address Health Disparities: 

      VIDEO: New Ideas in Addressing Cardiovascular Disease Disparities — Clyde Yancy, M.D 

      VIDEO: How Smartphones May Revolutionize Healthcare in the Developing World —Interview with Jacques Kpodonu, M.D. 

      VIDEO: Reducing Hypertension Among African-Americans — Interview with Kim Allan Williams, Sr., M.D. 

      Cardiovascular Ultrasound | July 20, 2022

      Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it easy for users to interpret what they are seeing. The TrueVue feature enhances the sense of depth and space, producing images that appear natural and realistic to the human eye.  

      Watch the video to check out how TrueVue can help improve views of LAA and MV morphology. 

      Cardiovascular Ultrasound | July 07, 2022

      Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to every echo exam. The AI-empowered algorithm delivers fast and consistent measurements – in half the time of manual methods.*  

      Watch the video to see how you can put “smart”  to work with the latest AI-powered quantification tools. 

      *External study with external sonographers comparing the results of 18 exams with and without AutoMeasure

      Cardiovascular Ultrasound | June 14, 2022

      The X5-1c transducer from Philips provides enhanced clinical information in transthoracic imaging over a standard phased array transducer. When combined with nSIGHT Plus image formation on the EPIQ CVx cardiology ultrasound system, the X5-1c transducer enables image quality rarely seen from a transthoracic transducer. 

      Watch the video to learn about the benefits which may include decreased exam time due to faster access to echo windows, increased confidence in quantification results and more. 

      Cardiovascular Ultrasound | May 31, 2022

      Philips recently announced an update to their flagship EPIQ CVx premium cardiology ultrasound system. Watch the video to learn about the latest features including the next-generation nSIGHT Plus imaging architecture system that leverages both hardware and software to support sophisticated image formation and enhanced image quality.

      Cardiac Imaging | February 01, 2022

      Interview with Campbell Rogers, M.D., chief medical officer of HeartFlow which has developed a CT image-based fractional flow reserve (FFR-CT) algorithm. The technology was recently included as a recommendation for front line chest pain evaluations in the 2021 ACC/AHA chest pain evaluation guidelines.

      The new guidelines gave high levels of evidence for the use of computed tomography and FFR-CT cardiac imaging as front line imaging modalities for chest pain evaluation.

      Related Chest Pain Imaging Content:

      First International Chest Pain Diagnosis Guidelines Released

      VIDEO: Why the ASNC Did Not Endorse the 2021 Chest Pain Guidelines — Interview with ASNC President Dennis Calnon, M.D.

       

      Coronavirus (COVID-19) | February 01, 2022

      Campbell Rogers, M.D., chief medical officer of HeartFlow, explains how hospitals are using CT image-based fractional flow reserve (FFR-CT) assessments to speed throughput of patients in emergency rooms and reduce the need for diagnostic angiograms during the COVID-19 pandemic.

       

      Cardiac Imaging | February 01, 2022

      American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac imaging for McConnell Heart Hospital at Riverside Methodist Hospital, and director of nuclear imaging for Ohio Health Heart and Vascular Physicians in Columbus, explains why the society did not endorse the first-ever U.S. or international guideline for the evaluation and diagnosis of patients with acute or stable chest pain.

      Nuclear myocardial perfusion imaging (MPI) has been a gold-standard for evaluation of coronary disease in patients for years, and it is included in the new guidelines. However, computed tomography angiography (CTA) has seen immense growth over the past decade and gained a prominent position in the guidelines as a front line imaging modality. This is due to nearly all hospital emergency rooms now having access to CT systems capable of performing immediate cardiac exams. CT has been seen mainly as an anatomical imaging test, but it also can be used for myocardial perfusion imaging using iodine contrast. While CT has had limits with its ability to image through heavily calcified vessels or stents, that is changing with new CT technologies now coming into service.

      One new CT technology that is prominently included I the new chest pain guidelines is CT fractional flow reserve (FFR-CT) imaging.  This uses a computational fluid dynamics algorithm to analyze a patient's CTA. It sends back a report and an interactive 3D reconstruction of all the coronary vessels that shows a color coded drop in FFR ratios, which is a measure of blood flow. Past a certain threshold, the reduced flow needs to be treated with revascularization. Lower level blockages can be treated with drug therapies. FFR-CT is widely expected in the coming years to become a gate keeper for invasive diagnostic angiograms. The hope is it will eliminate the need for the majority of cath lab angiogram exams and only send patients to the lab that need a stent or angioplasty. 

      However, the ASNC had major issues with FFR-CT being included in the chest pain guidelines. Its board members argued there is need for more evidence and there should have been more information contraindications for its use, which was included on other imaging modalities in the guidelines. They also argued access to the technology has been very limited. Calnon explains more detail in the video on why this was a sticking point and caused the ASNC to not endorse the guidelines.

      Read more in the article — First International Chest Pain Diagnosis Guidelines Released

      Nuclear Imaging | February 01, 2022

      American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac imaging for McConnell Heart Hospital at Riverside Methodist Hospital, and director of nuclear imaging for Ohio Health Heart and Vascular Physicians in Columbus, offers a concise overview of new technologies that are enhancing cardiac nuclear imaging. He also explains some of the new developments and uses for PET and SPECT imaging technology.

      Find more nuclear imaging technology news

       

      Coronavirus (COVID-19) | January 25, 2022

      Siddharth Singh, M.D., director of the COVID-19 heart program, staff cardiologist and echocardiographer, Cedars-Sinai Hospital, explains what has been learned in the first year of the hospital's long-COVID clinic. Cedar-Sinai was one of the first hospitals in the U.S. to create a cardiac long-COVID clinic. As of January 2022, the clinic has been more than 120 long-COVID patients with cardiac specific complains. 

      "Depending on what study you read, a percentage of patients with acute COVID infection will go on to develop long-lasting sequelae, but typically the percentage falls over time," explained Siddharth Singh, M.D., director of the COVID heart program, staff cardiologist and echocardiographer, Cedars-Sinai Hospital.

      He said studies show between 10-25 percent of COVID patients will experience at least one disabling long-COVID symptom six months after their acute infection.

      Cedars-Sinai long-COVID has seen over 500 patients since late 2020. Of these, 120 were referred for cardiac evaluations. The most common presentations in those patients include:
         • Shortness of breath
         • Exertional intolerance
         • Chest pain
         • Heart palpitations  
         • Sensations of light-headedness and dizziness
         • Insomnia
         • Brain fog 
         • Constipation
         • Diarrhea
         • Numbness or tingling in the extremities
         • Longer lasting issues with smell and taste

      Singh also said many patients experience anxiety and depression due to the continued symptoms, and are concerned the issues they have from COVID may be permanent. Both Baggish and Trivax also reported seeing these issues in many of their patients.

      In a smaller subset of patients these clinics have found lingering pericarditis or myocarditis. Most of these patients reported developing chest pain within two week or so after their acute infection. Singh said abnormalities can be imaged using echo and MRI.

      "They do typically have abnormalities on imaging. But reassuringly, of all the patients who came to our clinic with these issues, we did not see any decline in left ventricular ejection fraction or systolic function," Singh stressed.

      Patients with lingering pericarditis or myocarditis issues are treated with anti-inflammatories. Singh reinforced that the number of patients treated for this have been very low.

      Singh said the arrhythmias he has seen include atrial fibrillation (AF) and supraventricular tachycardia. He noted ventricular tachycardia is very rare in these patients. In discussions with his electrophysiology (EP) colleagues, Singh believes the issues with post-COVID arrhythmias often comes down to the substrate of the patient's heart. He said the more cardiovascular disease, cardiomyopathy, scarring, or previous AF a patient has, the more predisposed they are to developing an arrhythmia after a COVID infection. 

      Watch more of the interview with Singh in the VIDEO: Examination of Cardiac COVID Long-Haulers
       

      Related Long-COVID Content:

      What We Know About Cardiac Long-COVID Two Years Into the Pandemic 

      VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.

      VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.

      VIDEO: Examination of Cardiac COVID Long-Haulers — Interview with Siddharth Singh, M.D.

      Find more COVID news and video

       

      Coronavirus (COVID-19) | January 25, 2022

      Siddharth Singh, M.D., director of the COVID-19 heart program, staff cardiologist and echocardiographer, Cedars-Sinai Hospital, explains how they work up cardiac patients in the Cedars-Sinai long-COVID clinic. He goes through the list of exams  and labs they use in these patients.

      Cardiac patients at the Cedar-Sinai long-COVID clinic are evaluated with a basic physical exam, extensive family and medical history, an ECG, basic labs that include troponin and BNP, D-dimer, A1C, lipid panel and a metabolic profile since many patients have become much less active during the pandemic. Patients with symptoms are evaluated with an echocardiogram, including global longitudinal strain. If patients have abnormalities on the echo, or if there is suspected pericarditis or myocarditis, the patient is referred for a cardiac MRI with contrast. 

      Watch more of this interview in the VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital 

      Related Long-COVID Content:

      What We Know About Cardiac Long-COVID Two Years Into the Pandemic 

      VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.

      VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.

      VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.

      Find more COVID news and video

       

      Coronavirus (COVID-19) | January 24, 2022

      Justin Trivax, M.D., an interventional cardiologist who works with long-COVID patients at Beaumont Hospital, explains some of the common symptoms and their prevalence in the Beaumont long-COVID clinic. 

      COVID long hauler syndrome is no longer seen as a big mystery because large numbers of these patients have been seen and treated. The bottom line is that while long-hauler symptoms are an issue for patients, they do not appear to be life-threatening and the big fear of large numbers of new heart failure patients post infection has not materialized.

      "Interestingly, the patients do get better. It is a slow process, but by the one-year point we do see improvement in patients with this prolonged syndrome," reassured Trivax.

      Many of the patients Trivax has seen only had a mild case of COVID, but presenting months later with cardiac issues. Trivax said these patients often test troponin positive. The question as to what is causing this often results in a cardiac MRI.

      "There are also patients who had very mild symptoms [during their COVID infection] and those patients don't have a major event, however, they may have those prolonged symptoms," Trivax said. "We see this in the MRI studies that have been performed. But, what these abnormal cardiac MRIs really mean, we don't quite know. We don't have any long-term data for these COVID patients."

      Read more of his observations in the article What We Know About Cardiac Long-COVID Two Years Into the Pandemic

      Related Long-COVID Content:

      What We Know About Cardiac Long-COVID Two Years Into the Pandemic 

      VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.

      VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.

      VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.

      VIDEO: Examination of Cardiac COVID Long-Haulers — Interview with Siddharth Singh, M.D.

      Find more COVID news and video

      Coronavirus (COVID-19) | January 20, 2022

      Aaron Baggish, M.D., director of the cardiovascular performance program, Mass General Hospital, has been involved in the care of cardiac COVID-19 long-hauler patients and monitoring athletes recovering from COVID the past two years.

      He spoke to DAIC a year ago in late 2020 about the beginning of the Mass General monitoring of long-COVID patients and he shares what they have learned over the past year. He said the common long-term issues include arrhythmias, brain fog and other issues. Baggish also explains what they do to evaluate post-COVID infection patients with complaints or odd presentations weeks or months after their acute phase of infection ended.

      Watch the 2020 interview with Baggish on long-COVID — VIDEO: Lingering Myocardial Involvement After COVID-19 Infection

       

      Related Long-COVID Content:

      What We Know About Cardiac Long-COVID Two Years Into the Pandemic 

      VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.

      VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.

      VIDEO: Examination of Cardiac COVID Long-Haulers — Interview with Siddharth Singh, M.D.

      VIDEO: What Are The Long-term Cardiac Impacts of COVID-19 Infection — Interview with Todd Hurst, M.D.

      VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.

      Find more COVID news and video

      Magnetic Resonance Imaging (MRI) | January 18, 2022

      Orlando Simonetti, Ph.D., professor, cardiovascular medicine, worked with Siemens to help develop a new, lower-field magnetic resonance imaging (MRI) system, the Magnetom Free.Max. It can scan patients that previously may have been contraindicated because of implantable medical devices. The first system installed in the U.S. is at The Ohio State University Wexner Medical Center. It has a much lower magnetic field and a larger patient opening, removing barriers to MRI imaging for many patients.

      Simonetti and his colleagues developed new techniques to boost the signal-to-noise ratio in MRI machines, which allowed the creation of a machine with a lower magnetic field strength that still enables high quality images.

      The system gained FDA clearance in July 2021 and was featured by Siemens at the Radiological Society of North America (RSNA) 2021 meeting.

      The interview and footage was provided by The Ohio University State University Wexner Medical Center.

      Read more in the article New FDA-approved MRI Expands Access to Life-saving Imaging.

       

      Artificial Intelligence | January 13, 2022

      Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by vendors Aidoc and Viz.AI at the 2021 Radiological Society of North America (RSNA) 2021 meeting.

      The AI scans computed tomography (CT) image datasets as they came off the imaging system and looked for evidence of PE. If detected by the algorithm, it immediately sends an alert to the stroke care team members via smartphone messaging. This is done before the images are even loaded into the PACS. The radiologist on the team can use a link on the app to open the CT dataset and has basic tools for scrolling, windowing and leveling to determine if there is a PE and the severity. The team can then use the app to send messages, access patient information, imaging and reports. This enabled them all to be on the same page and can communicate quickly via mobile devices, rather than being required to use dedicated workstations in the hospital. 

      Both vendors showed similar apps for stroke at RSNA 2019. That idea for rapid alerts, diagnosis and communications for acute care teams has now expanded to PE and also for aortic dissection and abdominal aortic aneurysms (AAA). AI.Viz and Aidoc are looking at expanding this type of technology for other acute care team rolls, including heart failure response. 

      Read more about this technology in the article AI Can Facilitate Automated Activation of Pulmonary Embolism Response Teams.

      Find more AI news

      Find more RSNA news and video

       

       

      Cath Lab | January 13, 2022

      Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath labs across the country. Kootenai Health in Coeur d'Alene Idaho has a single cath lab performing more than 2,000 cases per year. Diane Penkert, executive director of heart and vascular services, discusses how the implementation of the Philips Performance Bridge analytics platform has enabled them to better leverage cardiovascular procedure data.

      Heart Failure | January 11, 2022

      The University of Maryland Medical Center (UMMC) announced the first successful transplant of a genetically modified pig’s heart into a human patient took place Jan. 9, 2022. The innovative procedure may pave the way to eliminating the current heart transplant wait lists. The cardiologists who developed this procedure believe in the near future, an unlimited number of pig hearts could be used to allow heart transplants in any patients who need them on demand, and regardless of the medical requirements that currently limit access to human heart transplants.

      Cardiac surgeons Muhammad M. Mohiuddin, M.D., scientific and program director, Cardiac Xenotransplantation Program, University of Maryland, and Bartley P. Griffith, M.D., M.D., explain how the procedure and technology works. They surgically transplanted a pig heart into the human patient after the patient had no options left and did not qualify for the heart transplant list. The patient was surviving in the hospital only through the use of an ECMO heart-lung machine.

      The patient, 57-year-old Maryland resident David Bennett, was granted a FDA emergency authorization for the surgery on New Year’s Eve through its expanded access (compassionate use) provision. It is used when an experimental medical product, in this case the genetically-modified pig’s heart, is the only option available for a patient faced with end-stage heart failure, a serious or life-threatening medical condition. The authorization to proceed was granted in the hope of saving the patient’s life.

      “This was a breakthrough surgery and brings us one step closer to solving the organ shortage crisis. There are simply not enough donor human hearts available to meet the long list of potential recipients,” said Griffith, the Thomas E. and Alice Marie Hales Distinguished Professor in Transplant Surgery at UMSOM. “We are proceeding cautiously, but we are also optimistic that this first-in-the-world surgery will provide an important new option for patients in the future.”

      This video includes video footage from the historic procedure and interviews with Griffith, Mohiuddin and other officials at University of Maryland Medical Center and the University of Maryland School of Medicine.

      Read more in the article First Human Receives a Pig Heart Transplant.

      Transplanting Pig Hearts Into Humans One Step Closer

      Coronavirus (COVID-19) | December 14, 2021

      Jean Jeudy, M.D., professor of radiology and vice chair of informatics at the University of Maryland School of Medicine, presented a late-breaking study at the 2021 Radiological Society of North America (RSNA) meeting on COVID-19 linked myocarditis in college athletes. 

      A small but significant percentage of college athletes with COVID-19 develop myocarditis, a potentially dangerous inflammation of the heart muscle, that can only be seen on cardiac MRI, according to the study Jeudy presented. Myocarditis, which typically occurs as a result of a bacterial or viral infection, can affect the heart’s rhythm and ability to pump and often leaves behind lasting damage in the form of scarring to the heart muscle. It has been linked to as many as 20% of sudden deaths in young athletes. The COVID-19 pandemic raised concerns over an increased incidence of the condition in student-athletes.

      For the new study, clinicians at schools in the highly competitive Big Ten athletic conference collaborated to collect data on the frequency of myocarditis in student-athletes recovering from COVID-19 infection. Conference officials had required all athletes who had COVID-19 to get a series of cardiac tests before returning to play, providing a unique opportunity for researchers to collect data on the athletes’ cardiac status.

      Jeudy serves as the cardiac MRI core leader for the Big Ten Cardiac Registry. This registry oversaw the collection of all the data from the individual schools of the Big Ten conference. He reviewed the results of 1,597 cardiac MRI exams collected at the 13 participating schools. 

      Thirty-seven of the athletes, or 2.3%, were diagnosed with COVID-19 myocarditis, a percentage on par with the incidence of myocarditis in the general population. However, an alarmingly high proportion of the myocarditis cases were found in athletes with no clinical symptoms. Twenty of the patients with COVID-19 myocarditis (54%) had neither cardiac symptoms nor cardiac testing abnormalities. Only cardiac MRI identified the problem.

      Read more details in the article COVID-19 Linked to Heart Inflammation in College Athletes.

      Related COVID-19 Imaging and Myocarditis Content:

      Overview of Myocarditis Cases Caused by the COVID-19 Vaccine

      COVID-19 Linked to Heart Inflammation in College Athletes — RSNA 2021 late-breaker

      VIDEO: Cardiac MRI Assessment of Non-ischemic Myocardial Inflammation Caused by COVID-19 Vaccinations — Interview with Kate Hanneman, M.D.

      Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents

      Large International Study Reveals Spectrum of COVID-19 Brain Complications - RSNA 2021 late-breaker

      COVID-19 During Pregnancy Doesn’t Harm Baby’s Brain

      VIDEO: Large Radiology Study Reveals Spectrum of COVID-19 Brain Complications — Interview with Scott Faro, M.D.

      FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets

      Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination

      Radiation Dose Management | December 10, 2021

      The vendor Radiaction introduced a new type of scatter radiation protection shielding system that mounts to the angiography system in the cath lab. It was shown for the first time at the 2021 Radiological Society of North America (RSNA) annual meeting.

      The system uses a motorized series of tungsten-polymer radiation shield plates that extend down from the detector, and up from the X-ray source, to the patient and bottom of the table. This greatly reduces scatter radiation in the lab, by as much as 92% according to the company's research. 

      The shields are deployed using a table-side controller. The shield has sensors to stop extending when it comes close to the patient or the table. The shield can be partly pulled back to enable panning the table. The company said the shield can be mounted on existing angiography C-arms.

      It has CE mark and is installed clinically in two cath labs in Israel. The company hopes to submit for U.S. FDA review in 2022.

      Related Cath Lab Radiation Dose Reduction Content:

      Defining the Cath Lab Workplace Radiation Safety Hazard

      VIDEO: Minimizing X-ray Exposure to Physicians During Interventional Procedures With the ControlRad System — Interview with Dr. Simon Dixon

      Medical Imaging Radiation Levels in U.S. Dropped Over Past Decade

      Philips Developing X-ray Free Cath Lab Imaging to Replace or Supplement Angiography

      VIDEO: Reducing Cath Lab Radiation Dose at Henry Ford Hospital

      VIDEO: Technologies and Techniques to Reduce Radiation Dose in the Cardiac Cath Lab — Interview with Akshay Khandelwal, M.D.

      Dose-Lowering Practices for Cath Lab Angiography

      5 Technologies to Reduce Cath Lab Radiation Exposure

      VIDEO: Heart Surgeon Shares Effects of Fluoroscopic Radiation Exposure

      Helping Interventional Cardiologists Reduce Exposure to Ionizing Radiation

      14 Ways to Reduce Radiation Exposure in the Cath Lab

      Subscribe Now